EA201491362A1 - Анестезирующие соединения и способы их применения - Google Patents

Анестезирующие соединения и способы их применения

Info

Publication number
EA201491362A1
EA201491362A1 EA201491362A EA201491362A EA201491362A1 EA 201491362 A1 EA201491362 A1 EA 201491362A1 EA 201491362 A EA201491362 A EA 201491362A EA 201491362 A EA201491362 A EA 201491362A EA 201491362 A1 EA201491362 A1 EA 201491362A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
anesthyzing
methods
application
formula
Prior art date
Application number
EA201491362A
Other languages
English (en)
Other versions
EA027976B1 (ru
Inventor
Дуглас Е. Райнес
Саид Шавкат Хусейн
Джон С.Р. Рэндл
Original Assignee
Дзе Дженерал Хоспитал Корпорейшн
Анновейшн Биофарма, Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Дженерал Хоспитал Корпорейшн, Анновейшн Биофарма, Ллк filed Critical Дзе Дженерал Хоспитал Корпорейшн
Publication of EA201491362A1 publication Critical patent/EA201491362A1/ru
Publication of EA027976B1 publication Critical patent/EA027976B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

В данном изобретении предложены соединения формулы (I)В изобретении также предложены фармацевтическая композиция, содержащая соединение формулы (I) и фармацевтически приемлемый носитель, и способ обеспечения анестезии у субъекта путем введения такой фармацевтической композиции.
EA201491362A 2012-01-13 2013-01-11 Анестезирующие соединения и способы их применения EA027976B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261586450P 2012-01-13 2012-01-13
US201261622627P 2012-04-11 2012-04-11
PCT/US2013/021245 WO2013106717A1 (en) 2012-01-13 2013-01-11 Anesthetic compounds and related methods of use

Publications (2)

Publication Number Publication Date
EA201491362A1 true EA201491362A1 (ru) 2014-12-30
EA027976B1 EA027976B1 (ru) 2017-09-29

Family

ID=48781947

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491362A EA027976B1 (ru) 2012-01-13 2013-01-11 Анестезирующие соединения и способы их применения

Country Status (23)

Country Link
US (4) US9156825B2 (ru)
EP (2) EP2802325B1 (ru)
JP (1) JP6196986B2 (ru)
CN (2) CN104168899B (ru)
AU (1) AU2013207811B2 (ru)
BR (1) BR112014017230A2 (ru)
CA (1) CA2861071C (ru)
CY (1) CY1118842T1 (ru)
DK (1) DK2802325T3 (ru)
EA (1) EA027976B1 (ru)
ES (1) ES2617536T3 (ru)
HR (1) HRP20170330T1 (ru)
HU (1) HUE030892T2 (ru)
IN (1) IN2014DN06132A (ru)
LT (1) LT2802325T (ru)
NZ (1) NZ627274A (ru)
PL (1) PL2802325T3 (ru)
PT (1) PT2802325T (ru)
RS (1) RS56025B1 (ru)
SG (1) SG11201403980VA (ru)
SI (1) SI2802325T1 (ru)
WO (1) WO2013106717A1 (ru)
ZA (1) ZA201405248B (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE058909T2 (hu) * 2015-10-10 2022-09-28 Jiangsu Nhwaluokang Pharmceutical Res And Development Co Ltd Etomidátszármazék és köztitermék, eljárás elõállítására és alkalmazása
CN105663042A (zh) * 2016-02-03 2016-06-15 北京蓝丹医药科技有限公司 一种稳定的麻醉药物脂肪乳及其制备方法
CN107382870A (zh) * 2016-05-17 2017-11-24 四川海思科制药有限公司 N‑取代咪唑羧酸酯类化合物及其制备方法和在医药上的用途
CN107445898A (zh) * 2016-05-30 2017-12-08 四川海思科制药有限公司 N‑取代咪唑羧酸酯类化合物及其制备方法和在医药上的用途
CN107522662A (zh) * 2016-06-16 2017-12-29 四川海思科制药有限公司 N‑取代咪唑羧酸酯类化合物及其制备方法和在医药上的用途
CN107641105A (zh) * 2016-07-22 2018-01-30 四川海思科制药有限公司 N‑取代咪唑羧酸酯类化合物及其制备方法和在医药上的用途
CN106432163A (zh) * 2016-09-29 2017-02-22 山东东方农药科技实业有限公司 一种螺环内酯类化合物、其合成方法以及其用途
CN107652239B (zh) * 2017-02-24 2020-08-04 四川大学华西医院 N-取代咪唑羧酸酯类化合物、制备方法及用途
CN109776509B (zh) * 2018-01-30 2023-07-07 成都麻沸散医药科技有限公司 一种n-取代咪唑甲酸酯类衍生物及其用途
CN109053410A (zh) * 2018-08-06 2018-12-21 兰博尔开封科技有限公司 一种合成1-羟基环己基甲酸的新工艺及应用
EP3858386A4 (en) 2018-09-26 2022-10-12 Jiangsu Hengrui Medicine Co., Ltd. LIGAND-DRUG CONJUGATE OF AN EXATECAN ANALOG, METHOD FOR PREPARATION AND THEIR USE
WO2020063673A1 (zh) 2018-09-30 2020-04-02 江苏恒瑞医药股份有限公司 抗b7h3抗体-依喜替康类似物偶联物及其医药用途
CN109761906B (zh) * 2019-03-02 2023-08-11 成都麻沸散医药科技有限公司 一种取代咪唑甲酸酯类衍生物及其用途
CN110003188B (zh) * 2019-03-27 2022-08-26 成都麻沸散医药科技有限公司 取代吡咯甲酸酯类衍生物及其用途
JP7467610B2 (ja) 2019-09-18 2024-04-15 バイリ-バイオ(チェンドゥ)ファーマスーティカル シーオー.,エルティーディー. カンプトテシン誘導体及びその複合体
JP2022551176A (ja) * 2019-10-11 2022-12-07 成都麻沸散医薬科技有限公司 置換窒素複素環化合物およびその麻酔作用
CN112174890B (zh) * 2020-10-09 2022-05-27 成都麻沸散医药科技有限公司 酮取代杂环化合物及其麻醉作用
CN110669017B (zh) * 2019-10-11 2023-08-04 成都麻沸散医药科技有限公司 多取代三唑甲酸酯类衍生物及其用途
WO2021115426A1 (zh) 2019-12-12 2021-06-17 江苏恒瑞医药股份有限公司 抗密蛋白抗体药物偶联物及其医药用途
MX2022007312A (es) 2019-12-16 2022-07-13 Jiangsu Hengrui Medicine Co Conjugado anti-cea-anticuerpo-eactonon analogo y uso medico del mismo.
JP2023511163A (ja) 2020-01-22 2023-03-16 上海森輝医薬有限公司 エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用
WO2021147993A1 (zh) 2020-01-22 2021-07-29 江苏恒瑞医药股份有限公司 抗trop-2抗体-依喜替康类似物偶联物及其医药用途
AU2021243080A1 (en) 2020-03-25 2022-09-22 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Preparation method for antibody medicament conjugate
MX2022011808A (es) 2020-03-25 2022-12-06 Jiangsu Hengrui Pharmaceuticals Co Ltd Conjugado de anticuerpo anti-psma-analogo de exatecan y uso medico del mismo.
CA3175733A1 (en) 2020-03-25 2021-09-30 Shanghai Hengrui Pharmaceutical Co., Ltd. Pharmaceutical composition comprising antibody drug conjugate and use thereof
WO2023001300A1 (zh) 2021-07-22 2023-01-26 上海森辉医药有限公司 艾日布林衍生物的药物偶联物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3354173A (en) 1964-04-16 1967-11-21 Janssen Pharmaceutica Nv Imidazole carboxylates
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CA1066709A (en) 1975-03-10 1979-11-20 Walter A.M. Helsen Preparation of loweralkyl imidazole carboxylates
US4038286A (en) 1975-03-10 1977-07-26 Janssen Pharmaceutica N.V. Racemates and optical isomers of 1-(1-phenylethyl)-1h-imidazole-5-carboylic acid derivatives
GR64915B (en) 1978-09-14 1980-06-09 Janssen Pharmaceutica Nv Improved etomidate-containing compositions
EP0277384A3 (en) 1986-12-24 1990-05-23 Janssen Pharmaceutica N.V. 1h-imidazole-5-carboxylic acid derivatives
US4878940A (en) 1987-04-02 1989-11-07 Janssen Pharmaceutica N.V. Herbicidal 1,5-substituted 1H-imidazoles
AR245694A1 (es) 1989-01-31 1994-02-28 Merrell Dow Pharma Procedimiento para la preparacion de nuevos derivados de acidos aril- o heteroaril-1-alquilpirrol-2-carboxilicos utiles como inhibidores de interleuquina-1
US5041554A (en) 1989-01-31 1991-08-20 Merrell Dow Pharmaceuticals Inc. Novel aryl-or heteroaryl-1-alkyl-pyrrole-2-carboxylic acid compounds useful in treating interleukin-1 mediated conditions
US5019583A (en) 1989-02-15 1991-05-28 Glaxo Inc. N-phenyl-N-(4-piperidinyl)amides useful as analgesics
US5242939A (en) * 1990-09-28 1993-09-07 Warner-Lambert Company Anilide derivatives with angiotensin ii antagonist properties
JP3374922B2 (ja) 1991-05-09 2003-02-10 日産化学工業株式会社 複素環式第3級アミンの製造方法
JPH06345728A (ja) 1993-06-11 1994-12-20 Nissan Chem Ind Ltd N−置換アゾール誘導体の製造方法
US5466700A (en) 1993-08-30 1995-11-14 Glaxo Wellcome Inc. Anesthetic use of N-phenyl-N-(4-piperidinyl)amides
US5997898A (en) 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US5756528A (en) 1995-06-06 1998-05-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2441744C (en) 2001-03-20 2011-07-12 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US6897319B2 (en) 2001-12-27 2005-05-24 Ortho-Mcneil Pharmaceutical, Inc. Useful aroyl pyrrole heteroaryl methanones and methanols
US7189859B2 (en) 2003-08-06 2007-03-13 Ilse Zolle Radiolabelled phenylethyl imidazole carboxylic acid ester derivatives
US20080206138A1 (en) 2003-08-06 2008-08-28 Ilse Zolle Radiolabelled Phenylethyl Imidazole Carboxylic Acid Ester Derivatives
AU2005277203A1 (en) 2004-08-20 2006-03-02 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
US7592362B2 (en) * 2006-01-19 2009-09-22 Pfizer Limited Substituted imidazoles
KR101378821B1 (ko) 2006-01-24 2014-03-28 니폰 조키 세야쿠 가부시키가이샤 신규 히스티딘 유도체
EP2035393A2 (en) 2006-06-09 2009-03-18 GE Healthcare Limited Synthesis and evaluation of 18f-labelled alkyl-1-[(r)-1-phenylethyl]-1h-imidazole-5-carboxylate as a tracer for the quantification of beta-11-hydroxylase enzyme in the adrenal glands
JP5301441B2 (ja) 2007-07-23 2013-09-25 日本臓器製薬株式会社 新規ヒスチジン誘導体
JP5580287B2 (ja) * 2008-03-31 2014-08-27 ザ ジェネラル ホスピタル コーポレイション 改善された薬物速度論的および薬力学的特性を有するエトミデート類似体
CN102548964B (zh) * 2009-07-10 2014-09-24 通用医疗公司 不抑制肾上腺皮质类固醇合成的依托咪酯类似物

Also Published As

Publication number Publication date
EP2802325A4 (en) 2015-06-10
JP6196986B2 (ja) 2017-09-13
CA2861071A1 (en) 2013-07-18
SG11201403980VA (en) 2014-08-28
ZA201405248B (en) 2017-04-26
BR112014017230A2 (pt) 2020-11-24
SI2802325T1 (sl) 2017-04-26
US20180098968A1 (en) 2018-04-12
US9522136B2 (en) 2016-12-20
HRP20170330T1 (hr) 2017-04-21
LT2802325T (lt) 2017-03-10
DK2802325T3 (en) 2017-03-13
CY1118842T1 (el) 2018-01-10
ES2617536T3 (es) 2017-06-19
JP2015508415A (ja) 2015-03-19
AU2013207811B2 (en) 2017-08-10
CN104168899B (zh) 2017-04-05
PT2802325T (pt) 2017-03-01
PL2802325T3 (pl) 2017-11-30
US20150328189A1 (en) 2015-11-19
CN104168899A (zh) 2014-11-26
CA2861071C (en) 2017-09-12
US9156825B2 (en) 2015-10-13
AU2013207811A1 (en) 2014-07-31
US20170273951A1 (en) 2017-09-28
CN107382812A (zh) 2017-11-24
EA027976B1 (ru) 2017-09-29
HUE030892T2 (hu) 2017-07-28
RS56025B1 (sr) 2017-09-29
EP2802325B1 (en) 2016-11-30
WO2013106717A1 (en) 2013-07-18
EP2802325A1 (en) 2014-11-19
US20150203476A1 (en) 2015-07-23
EP3184512B1 (en) 2020-12-23
IN2014DN06132A (ru) 2015-08-14
EP3184512A1 (en) 2017-06-28
US10154991B2 (en) 2018-12-18
NZ627274A (en) 2015-10-30
US9820971B2 (en) 2017-11-21

Similar Documents

Publication Publication Date Title
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
PH12020550552A1 (en) Inhibitors of hepatitis c virus
PH12015501996A1 (en) Heterocyclic compounds and uses thereof
CY1120480T1 (el) Ενωσεις πυραζολοπυριμιδινης
CY1116987T1 (el) Συμπυκνωμενα ιμιδαζολυλιμιδαζολια ως αντιϊικες ενωσεις
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
EA201690598A1 (ru) Аминогетероарил бензамиды в качестве ингибиторов киназы
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
GEP201706671B (en) Heterocyclyl compounds as mek inhibitors
EA201590200A1 (ru) Модуляторы пути активации комплемента и их применение
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
MX2015003594A (es) Agente terapeutico o profilactico para sindrome de lisis tumoral.
EA201391525A1 (ru) Гликозидные производные и их применение для лечения диабета
EA201490756A1 (ru) Разагилина цитрамид
EA201500931A1 (ru) Производные пиридин-4-ила
MX364400B (es) Compuestos de tetraciclina.
EA201590364A1 (ru) Применение орвепитанта, его солей и кристаллических форм и композиций, его содержащих, для лечения зуда
EA201391524A1 (ru) Производные гликозида и их применение
EA201600323A1 (ru) Производные пиперазина и их применение в качестве лекарственного средства
EA201490573A1 (ru) Соединение бензотиазолона
CY1119984T1 (el) Σταθεροποιημενη αμορφη μορφη αγομελατινης, μια μεθοδος για την παρασκευη της και φαρμακευτικες συνθεσεις που την περιεχουν

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU